Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 19/20 | 0.84 |
| ▸ | EPHB4 | P54760 | 14/20 | 0.84 |
| ▸ | KDR | P35968 | 16/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.82 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906808 | 0.91 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2EGFR | |
| Hydrochloric Acid SCHEMBL907153 | 0.91 | EPHA2 (0.98) | EPHA2EPHB4KDRERBB2EGFR | |
| SCHEMBL906935 | 0.90 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2EGFR | |
| SCHEMBL907272 | 0.90 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2EGFR | |
| Hydrochloric Acid SCHEMBL907249 | 0.89 | EPHA2 (0.98) | EPHA2EPHB4KDRERBB2EGFR | |
| SCHEMBL907073 | 0.89 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2EGFR | |
| Hydrochloric Acid SCHEMBL910764 | 0.88 | EPHA2 (0.98) | EPHA2EPHB4KDRERBB2EGFR | |
| SCHEMBL906934 | 0.88 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2EGFR | |
| SCHEMBL13590284 | 0.84 | EPHA2 (0.90) | EPHA2EPHB4KDRERBB2 | |
| SCHEMBL3031854 | 0.81 | EPHA2 (0.85) | EPHA2EPHB4KDRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481001-B2 | Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer | EXELIXIS, INC. (US) | 2013-07-09 | — | — | US | disclosed |